Q-omics provides the consensus-scored DEFB110 profile across patient tissues and cancer cell-line models. DEFB110 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DEFB110 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, DEFB110 RNA expression shows 10,582 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight UCEC, THCA, and COAD as cancer lineages where DEFB110 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB110 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB110 survival associations across molecular data types. DEFB110 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB110 RNA expression–survival associations across cancer types. High DEFB110 expression shows unfavorable associations in UCEC, SKCM, KIRC, KIRP and LGG, but favorable associations in ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for DEFB110 RNA expression.
This table summarizes DEFB110 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB110. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB110 shows lower tumor expression in THCA. The THCA box plot shows higher DEFB110 RNA expression in normal versus tumor tissue (log2 FC = −0.066, t-test p = .022).
This table shows molecular features associated with DEFB110 in patient tissues and cancer cell lines. In patient samples, DEFB110 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB110 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
